- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Feraheme MRI/MRA
- Procedure
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 17,667 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- VAD044 Part I, VAD044 Part II
- Drug
- Lead sponsor
- Vaderis Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Bevacizumab (Avastin®)
- Drug
- Lead sponsor
- Hanny Al-Samkari, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hereditary Haemorrhagic Telangiectasia (HHT)
- Interventions
- Not listed
- Lead sponsor
- Ashley Nelson
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Arteriovenous Malformation, Hereditary Hemorrhagic Telangiectasia, Hematochezia, Melena
- Interventions
- Thalidomide
- Drug
- Lead sponsor
- Northport Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 3
- States / cities
- Augusta, Georgia • Worcester, Massachusetts • Northport, New York
- Conditions
- Epistaxis, Hereditary Hemorrhagic Telangiectasia
- Interventions
- Sclerotherapy, Standard Treatment
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia
- Interventions
- Pomalidomide
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Telangiectasia, Hereditary Hemorrhagic
- Interventions
- Pomalidomide Oral Product, Placebo oral capsule
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 11 more
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
- Interventions
- ATV-1601, Placebo
- Drug
- Lead sponsor
- Atavistik Bio, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Boston, Massachusetts • Rochester, Minnesota
- Conditions
- Pulmonary Arteriovenous Malformation
- Interventions
- Microvascular Plug (MVP), Amplatzer Vascular Plug (AVP), Detachable coils
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
- Interventions
- Topical sirolimus ointment
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Epistaxis
- Interventions
- Doxycycline, Placebo
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- TER-1754, Placebo
- Drug
- Lead sponsor
- Terremoto Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Osler-Rendu-Weber Disease, Osler-Rendu Disease, Telangiectasia, Hereditary Hemorrhagic
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- Transthoracic Contrast Echocardiogram
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Telangiectasia, Hereditary Hemorrhagic
- Interventions
- Pazopanib, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Augusta, Georgia • St Louis, Missouri + 2 more
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- ALN-6400, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Cypress, California • Gainesville, Florida + 5 more
- Conditions
- HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
- Interventions
- Bevacizumab, Placebo (Saline)
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- Submucosal Bevacizumab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- Bevacizumab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Not listed
- Lead sponsor
- Unity Health Toronto
- Other
- Eligibility
- Not listed
- Enrollment
- 2,272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2025
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Ultra-low dose chest CT
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- Pomalidomide
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 11
- States / cities
- San Diego, California • San Francisco, California • Gainesville, Florida + 8 more